10-K: Nutra Pharma Reports 2022 Net Income Amidst SEC Settlement, Leadership Change

Nutra Pharma Corp. reported a net income of $8.18 million for 2022, primarily driven by a non-cash gain from derivative revaluation, while facing a significant SEC settlement and a change in executive leadership.

Summary

• Nutra Pharma Corp. is a biopharmaceutical company focused on drugs for autoimmune disorders, viral diseases, and pain, alongside a line of over-the-counter (OTC) pain relief products.
• The company reported a net income of $8,176,871 for the year ended December 31, 2022, a significant improvement from a net loss of $13,095,521 in 2021.
• This net income was largely due to an $11,023,290 gain from the change in fair value of convertible notes and derivatives, a non-cash item.
• Total sales increased to $438,274 in 2022 from $97,735 in 2021, primarily driven by private label product sales to Avini Health, a related party.
• Operating losses remained substantial at $1,907,404 in 2022, slightly lower than $1,988,445 in 2021.
• The company continues to face substantial doubt about its ability to continue as a going concern due to recurring losses, a significant working capital deficit of $12,367,244, and a stockholders' deficit of $12,377,452 as of December 31, 2022.
• Key drug candidates include RPI-78M for neurological and autoimmune diseases (e.g., MS, AMN) and RPI-MN for viral diseases (e.g., HIV/AIDS, Herpes). RPI-78M has Orphan Designation for Pediatric Multiple Sclerosis.
• Research and development for drug candidates and clinical studies for pain relievers are delayed due to lack of funding, with an estimated $3,000,000 needed for current projects.
• The company settled a civil lawsuit with the SEC in March 2024, agreeing to pay $520,940 in disgorgement, $59,295 in prejudgment interest, and a $100,000 civil penalty, totaling $680,235.
• Rik J. Deitsch resigned as Chairman, CEO, and CFO in March 2024, replaced by Michael Flax, DDS, with Joe Lucas named as VP of Operations.
• Material weaknesses in internal control over financial reporting were identified, including insufficient accounting staff, inadequate segregation of duties, and limited checks and balances.
• The company moved its operations to a new facility in Boca Raton in September 2023, sharing space with Avini Health as part of contract manufacturing agreements.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, with substantial doubt about its ability to continue as a going concern, recurring operating losses, and significant deficits. While sales increased and a non-cash accounting gain led to net income, operational profitability remains elusive. Major legal issues with the SEC and internal control weaknesses further compound the negative outlook, despite some positive R&D developments and new management.

Positives

• Reported a net income of $8,176,871 for 2022, a significant turnaround from a $13,095,521 net loss in 2021.
• Total sales increased by 348% to $438,274 in 2022 from $97,735 in 2021, driven by private label manufacturing for Avini Health.
• Gross profit margin improved to 62.84% in 2022 from 57.78% in 2021, mainly due to decreased manufacturing costs.
• Received Orphan Drug Designation from the US-FDA for RPI-78M for the treatment of Pediatric Multiple Sclerosis, which may expedite regulatory review and reduce clinical trial costs.
• Expanded in-house manufacturing capabilities to include liquid filling, tube filling, and capsule production, leading to reduced product costs, higher margins, and faster product upgrades.
• Secured a contract manufacturing agreement with Avini Health, a related party, for dietary supplements and private label versions of OTC products.
• Net cash used in operating activities decreased by 56% to approximately $0.8 million in 2022, compared to $1.7 million in 2021, largely due to favorable changes in working capital.

Negatives

• Incurred significant net operating losses of $1,907,404 in 2022 and $1,988,445 in 2021, indicating that core operations are not profitable.
• Accumulated deficit reached $73,552,118 as of December 31, 2022, highlighting a long history of unprofitability.
• Maintained a significant working capital deficit of $12,367,244 and a stockholders' deficit of $12,377,452 at December 31, 2022.
• The reported net income in 2022 was primarily a non-cash gain of $11,023,290 from the change in fair value of convertible notes and derivatives, not from operational profitability.
• Settled an SEC lawsuit in March 2024, resulting in a total payment of $680,235 for disgorgement, prejudgment interest, and civil penalties.
• Experienced a 70% decrease in net cash provided by financing activities in 2022, down to $644,216 from $2,130,000 in 2021, mainly due to reduced proceeds from convertible notes.
• R&D and clinical studies for drug candidates and pain relievers are delayed due to a lack of adequate funding.
• Identified material weaknesses in internal control over financial reporting, including insufficient accounting staff, inadequate segregation of duties, and limited checks and balances.
• The company's common stock is considered a 'penny stock,' limiting its liquidity and market price due to SEC regulations.
• Dependence on a few major customers, with one customer accounting for 67% of total revenues in 2022, poses a concentration risk.

Risks

• Ability to continue as a going concern is in substantial doubt without obtaining adequate new debt or equity financing and achieving sufficient sales levels.
• Limited revenue-producing history with significant losses and expectation of continued losses for the foreseeable future.
• Requirement for additional financing to sustain operations; inability to secure it will prevent continued operations.
• History of failed distributors negatively affecting revenues and potential future sales if successful distributors are not found.
• Inability to sell a sufficient volume of products will prevent the company from continuing in business.
• Growth strategy may be unachievable or may not result in profitability due to factors like market acceptance, market penetration costs, manufacturing scalability, and regulatory compliance.
• Inability to manage growth effectively could prevent profitability, requiring expansion of management and key employees.
• Failure to protect proprietary technology (patents, trade secrets) could harm the business due to competitors designing around patents or costly litigation.
• Subject to substantial FDA regulations for Nyloxin and Pet Pain-Away, with non-compliance potentially leading to sales cessation or increased costs.
• Inability to provide scientific proof for product claims may adversely affect sales due to FDA or FTC scrutiny.
• None of the ethical drug candidates have received FDA approval, and the process is complex, costly, and lengthy, with no assurance of approval.
• Inability to secure sufficient cobra venom from available suppliers could lead to distribution delays and negative impact on brand reputation and operating results.
• Nyloxin and Pet Pain-Away products may be unable to compete effectively against more established competitors with greater resources and brand recognition.
• Product liability claims exceeding insurance limits could result in substantial legal costs or judgments, negatively impacting financial and operating results.
• Loss of key personnel (CEO, Operations Manager, Chief Scientific Officer) could materially adversely affect operations and financial results.
• Market for common stock is limited (OTC-Market), and penny stock rules adversely affect liquidity and market price.
• Sales of freely tradable shares could cause the market price of common stock to drop significantly.
• Future dilution from issuance of additional securities or exercise of options/warrants is possible.
• Negative net tangible book value means purchasers will suffer substantial dilution.
• No dividends expected in the foreseeable future as earnings will be retained for business development.
• Stock price volatility due to various factors including failure to generate revenue, meet expectations, or changes in market valuations.
• Biotechnology industry litigation is substantial and may lead to greater costs and unpredictable outcomes.
• Failure to comply with extensive legal/regulatory requirements in the healthcare industry could lead to increased costs, penalties, and business losses.

Future Outlook

The company plans to continue efforts to produce, market, and distribute its Nyloxin, Pet Pain-Away, Equine Pain-Away, and Luxury Feet branded products domestically and internationally. It aims to move RPI-78M into Phase I/II clinical studies for Pediatric MS by the end of 2025, leveraging its Orphan Designation. Mid-term strategy involves licensing AMN, MS, and HIV technologies within 5 years, contingent on adequate financing. Long-term goals include broader application of drugs in neurological, infectious, and autoimmune disorders, requiring strategic partnerships. The company will continue to identify biotechnology-related intellectual property and potential acquisition candidates. However, all planned studies and international expansion are contingent on securing adequate financing or generating sufficient revenues.

Management Comments

• "Our goal is that with Nyloxin, we can greatly reduce the instances of opiate abuse and overuse of NSAIDS in high risk groups like the US military."
• "We continue to identify biotechnology related intellectual property and companies with which we may potentially be able to enter into arrangements, agreements or to potentially acquire."
• "Our business plan will continue its efforts to produce, market and distribute our Nyloxin, Pet Pain-Away, Equine Pain-Away and Luxury Feet branded products both domestically and internationally."
• "We estimate that we will require approximately $600,000 to fund our existing operations over the next twelve months."
• "Our plan is to continue to increase sales of our products and attempt to secure adequate funding to bridge the commercialization of our Nyloxin and Pet Pain-Away products."
• "Our goal is to initiate these trials [Pediatric MS Phase I/II] in 2026."
• "Our management is responsible for establishing and maintaining adequate internal control over financial reporting."
• "To remedy these weaknesses [in internal controls], when financially able, we plan to supplement our accounting staff with additional experienced financial professionals, redefining and realigning responsibilities and by defining additional controls, reporting processes and procedures to address the accounting requirements and disclosures, and engage independent directors and a qualified independent audit committee."

Industry Context

The company operates in the highly competitive pain management and biopharmaceutical sectors. The global chronic pain treatment market is projected to reach $105.9 billion by 2025, driven by rising chronic conditions and an aging population. The multiple sclerosis drug market is also substantial, estimated at $21.26 billion globally in 2024, with significant growth expected. Nutra Pharma's focus on non-opioid pain relief and orphan drug indications aligns with growing market needs and regulatory incentives. However, it faces intense competition from major pharmaceutical companies with significantly greater financial and R&D resources, particularly in the biologics space (e.g., Amgen, Biogen, Novartis) and in venom-based therapeutics (e.g., Pentapharm, Elan). The market for nerve agent countermeasures also presents a niche opportunity, aligning with national defense priorities.

Comparison to Industry Standards

• Nutra Pharma's OTC pain relievers (Nyloxin, Pet Pain-Away) compete against established multi-billion dollar manufacturers and generic drug companies, which typically have far superior financial, technical, and marketing capabilities.
• In the MS market, Nutra Pharma's RPI-78M aims to compete with 15 approved drugs, including interferon-based therapies like Betaseron (Bayer), Avonex (Biogen), and Rebif (EMD Serono), which have annual sales exceeding $8 billion. The average annual cost of these drugs is high, with brand-name disease-modifying therapies costing around $94,000, suggesting a high barrier to entry and significant R&D investment required.
• The company's RPI-78 and RPI-70 drug candidates for pain are compared to opiate-based drugs like Dolantin and injectable treatments like Prialt (Elan). RPI-78 was calculated to be 150,000 times more potent than aspirin, and RPI-70 showed long-lasting effects without opioid side effects, suggesting potential competitive advantages if successfully developed and approved.
• In the venom-based drug market, Nutra Pharma competes with companies like Pentapharm (Batroxobin), Knoll Pharmaceutical (Ancrod), Bristol-Myers Squibb (Capoten), Medicure (Aggrastat), Millennium Pharmaceutical (Integrilin), Amylin Pharmaceuticals (Byetta), and Elan Pharmaceuticals (Prialt), all of whom leverage venoms for various therapeutic applications, indicating a specialized but competitive field.

Management Changes

Corporate Governance

Legal Proceedings

• **Paul Reid et al. v. Nutra Pharma Corp. et al. (Case No. CACE16015834):** A lawsuit filed on August 26, 2016, by former ReceptoPharm employees and a consultant seeking $315,000 for alleged unpaid amounts under a settlement agreement and wages. The case was confidentially settled on June 24, 2021, and the company considers it fully resolved.
• **CSA 8411, LLC v. Nutra Pharma Corp. (Case No. CACE 18-023150):** A lawsuit filed on October 12, 2018, to recover $100,000 allegedly owed under an amended promissory note. The company disputed the claim, citing valid defenses and fraudulent inducement. The case was settled on May 19, 2025, for $125,000, payable in an initial $35,000 payment and nine monthly payments of $10,000. A gain on settlement of $53,526 is expected upon full satisfaction of payment terms.
• **Securities and Exchange Commission v. Nutra Pharma Corporation, Erik Deitsch, and Sean Peter McManus (Case No. 2:18-cv-05459):** A lawsuit filed on September 28, 2018, alleging violations of federal securities laws, including unregistered offerings, false statements in press releases and filings, and manipulative trading. Final judgments were entered in March and May 2024, with the company agreeing to permanent injunctive relief and a total payment of $680,235 ($520,940 disgorgement, $59,295 prejudgment interest, $100,000 civil penalty). Former CEO Rik Deitsch received a three-year officer-and-director bar and penny-stock bar, and a total payment of $79,060. Sean Peter McManus received a two-year penny-stock bar and a total payment of $11,626.

Related Party Transactions

• The company acts as a product formulator and contract manufacturer for Avini Health, a company owned by the company's former chief executive officer, who is also Avini Health's chief scientific officer.
• Commencing in May 2022, the company sublets a portion of its space to Avini Health for a monthly rent of $5,000, with the first three months rent-free. Rental income of $25,000 was recorded in 2022.
• Net sales to Avini Health (a related party) amounted to $292,474 in 2022.
• The company had fully reserved receivables from companies owned by its former CEO, resulting in a bad debt expense of $71,796 in 2022 and $68,330 in 2021.
• As of December 31, 2022, the net balance due to Rik Deitsch and his controlled companies was $112,046, unsecured and accruing 4% interest.
• Accrued payroll due to officers was $1,213,693 in 2022 and $1,053,693 in 2021.
• Accrued interest to related parties was $149,909 in 2022 and $147,768 in 2021.
• Deferred revenue to a related party (Avini Health) was $181,515 in 2022.
• These transactions were not conducted at arm's length and may not reflect market terms.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from potential future capital raises and conversion of existing convertible debt. The penny stock designation and limited market liquidity make it difficult to sell shares. The SEC lawsuit and associated penalties, along with the resignation of the former CEO, could erode investor confidence. The substantial doubt about going concern status poses a fundamental risk to investment value.
• **Employees:** The company employs 6 individuals, including key management and scientific personnel. The ongoing financial struggles and need for additional funding could impact job security and compensation. The change in CEO and VP of Operations affects leadership and potentially company culture.
• **Customers:** Continued product availability for OTC pain relievers (Nyloxin, Pet Pain-Away) is dependent on the company's ability to sustain operations and manufacturing. Delays in R&D for ethical drugs mean potential new treatments for serious conditions like MS and HIV are not reaching patients as quickly as hoped.
• **Creditors:** The company has a significant amount of indebtedness, much of which is in default, and a substantial working capital deficit, indicating high credit risk. The SEC settlement adds to the financial burden.
• **Suppliers:** Dependence on cobra venom suppliers and the company's financial instability could affect its ability to make timely payments or secure necessary raw materials.

Next Steps

• Re-engage in the regulatory approval process for Nyloxin in Canada, with an expected re-engagement in 2026.
• Complete several human clinical studies aimed at comparing Nyloxin Extra Strength to prescription pain relievers, pending adequate financing.
• Reinitiate planned MS Neuropathic Pain Phase IV, Chronic Back Pain Phase I, and Chronic Back Pain Phase IV trials, pending adequate funding.
• Work with consultants to prepare a pre-IND meeting with the FDA to gain approval for a Phase I/II clinical study protocol in Pediatric MS.
• Initiate Phase I/II clinical studies in Pediatric MS with RPI-78M under Orphan Designation, with a goal to begin in 2026.
• Continue identifying biotechnology-related intellectual property and companies for potential arrangements, agreements, or acquisitions.
• Supplement accounting staff with additional experienced financial professionals, redefine responsibilities, and implement additional controls to address internal control weaknesses, when financially able.
• Engage independent directors and a qualified independent audit committee to remedy internal control weaknesses, when financially able.
• Engage third-party consultants to assist in accounting for complex transactions and disclosures until appropriate accounting personnel are hired.

Key Dates

Recommendation

Nutra Pharma Corp. presents an extremely high-risk investment profile. While the company reported a net income in 2022, this was a non-cash accounting gain from derivative revaluation, masking persistent operational losses and severe financial distress. The company explicitly states 'substantial doubt about our ability to continue as a going concern,' evidenced by significant accumulated, working capital, and stockholders' deficits. Liquidity is critically low, with negative cash flow from operations and a heavy reliance on external financing, which is uncertain. The recent SEC settlement, resulting in substantial penalties and the forced resignation of the former CEO, highlights severe governance and compliance issues. Material weaknesses in internal controls further undermine financial reliability. Despite some promising R&D in biopharmaceuticals and growth in private label sales, these positives are overshadowed by fundamental financial instability, regulatory challenges, and a highly competitive market. The stock's penny stock status and limited liquidity make it unsuitable for most investors. Given the profound financial and operational risks, a 'strong sell' recommendation is warranted.

Keywords

Biopharmaceutical, Pain Relief, Autoimmune Disorders, Viral Diseases, Multiple Sclerosis, Adrenomyeloneuropathy, HIV, Herpes, Orphan Drug, FDA Approval, Nyloxin, Pet Pain-Away, Equine Pain-Away, Luxury Feet, Cobra Venom, Contract Manufacturing, SEC Lawsuit, Going Concern, OTC Market, Biotechnology, Pharmaceuticals, Drug Development, Clinical Trials, Corporate Governance, Financial Reporting